CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that ...

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive ...

The MarketWatch News Department was not involved in the creation of this content. -- Financing led by US life sciences investor, BroadOak Capital Partners -- Investment to support expansion of US ...

Axol Bioscience has exceeded all expectations in its crowdfunding investment round. The game-changing stem cell tech company listed on SyndicateRoom seeking £600,000, but massive investor interest saw ...

Axol Bioscience and Censo Biotechnologies have merged to set up a one-stop-shop for induced pluripotent stem cells (iPSCs). IPSCs are derived from skin or blood cells that have been reprogrammed back ...

Take your neuroimmunology research to the next level! Our Human iPSC-derived Microglia are suitable for a variety of applications including in vitro disease models, phenotypic screening and immunology ...

CAMBRIDGE, England & EDINBURGH, Scotland & GRASSE, France--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today ...

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of ...

Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Axol Bioscience – a stem ...

CAMBRIDGE, England & EDINBURGH, Scotland, January 13, 2026--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and ...

Move expands iPSC‑derived retinal model portfolio and strengthens position in research Axol Bioscience has acquired the ophthalmology business of Newcells Biotech in a deal that broadens its range of ...